Different value-based payment approaches are evolving for different sorts of conditions, different sorts of financial circumstances, and other factors, explained Clifford Goodman, PhD, senior vice president and director, Center for Comparative Effectiveness Research, The Lewin Group.
This page contains sponsored advertising.
Different value-based payment approaches are evolving for different sorts of conditions, different sorts of financial circumstances, and other factors, explained Clifford Goodman, PhD, senior vice president and director, Center for Comparative Effectiveness Research, The Lewin Group.
Transcript
Has the move to value-based payments been happening as quickly as you expected?
With regard to the move toward value-based payments, it’s a couple interesting phenomena. One is that although most people might say that they’re disappointed in how quickly we’re moving to value-based payments, the very same people would probably say, “we didn’t realize how interesting and complex value-based payment is.”
So, although it seems to be taking some time, we’re also learning along the way. There’s no particular one right way to do value-based payment. Different value-based payment approaches are evolving for different sorts of conditions, different sorts of financial circumstances, and other factors are at work, as well. So, I would say that we are ramping up, but we’re learning how to do this piloting, experimenting, and getting feedback on what works.
In particular, some of the things that we’re noticing happen to be that it may be easy to conceptualize value-based payment, but how do you really operationalize it? Whose data are you going to use, how valid and rigorous are those data, who’s in charge of the data, who manages the data, who owns the data, and what sort of administrative burden is placed in the organization that’s charged with the data? And that’s just the data. So, again, overall ramping up gradually, but learning along the way. I’m still optimistic.
Semaglutide Eligibility Expands to Over Half of US Adults
November 21st 2024Over half of the US adult population may benefit from semaglutide, a drug primarily used for weight loss and diabetes, although concerns about access and cost persist, especially considering its potential for wider health applications.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen